Relating To Access To Treatment For Terminally Ill Patients.
Impact
If enacted, SB857 will amend Hawaii’s existing statutes to allow patients who have been unable to participate in clinical trials or exhaust other approved treatment options to access promising investigational therapies. Specifically, the bill outlines the circumstances under which a drug manufacturer can provide these therapies, emphasizing the rights of patients to make informed choices regarding their treatment options. This law could significantly alter the current regulatory landscape, offering new avenues for treatment during critical health crises.
Summary
SB857, known as the Right-to-Try Act, aims to provide patients with terminal illnesses access to investigational drugs and biological products that have not yet received approval from the U.S. Food and Drug Administration (FDA). The bill emphasizes the urgency for terminally ill patients, who may not have time to wait for standard approval processes to potentially receive treatments that could save their lives. Starting January 1, 2024, manufacturers are permitted to make these investigational drugs available to eligible patients, reflecting a trend where 41 other states have enacted similar right-to-try legislation.
Sentiment
The sentiment around SB857 appears to be largely positive among proponents, including patient advocacy groups and some lawmakers, who view it as a crucial step towards improving healthcare access for terminally ill patients. However, there are concerns raised by healthcare professionals regarding the safety and efficacy of investigational drugs that have not been fully vetted through the conventional approval process. The discussion reflects a balance between giving patients more choices and ensuring they are adequately protected by medical standards.
Contention
Notable points of contention include the potential risks involved for patients using unapproved drugs, as well as the responsibilities that fall on healthcare providers when recommending such treatments. Critics argue that without substantial protections in place, patients may be exposed to unsafe or ineffective treatments. Additionally, insurers are not mandated to cover the costs associated with these investigational drugs, potentially placing a financial burden on patients at a time when they are already facing significant health challenges.
Relating to advisory bodies for the Department of Family and Protective Services, including the creation of the child protective investigations advisory committee and the abolition of the Family and Protective Services Council.
Health: other; individualized investigational treatment for certain patients suffering from a life-threatening or severely debilitating illness; provide for. Amends title & secs. 1, 2, 3, 4, 5, 6 & 7 of 2014 PA 345 (MCL 333.26451 et seq.) & adds sec. 2a.